Approved Abstract: A Retrospective Observational Evaluation of OCM as Primary Therapy for a Thermal Burn Wound in an Adult Private Practice Wound Setting. The abstract will be presented at the 2026 Fall SAWC Conference, in Las Vegas, NV by Dr. Angelina Ferguson. Dr. Ferguson is the Chief Research Officer for Sygnola Research. Sygnola Research Headquarters are based in New Orleans, LA. OMEZA is also currently enrolling patients in 2 randomized clinical trials where advanced wound care is indicated following standard of care failure: Diabetic Foot Ulcer (NCT07161830) and Venous Leg Ulcer (NCT07754526) Please see OMEZA's website for all peer reviewed publications studying OCM (OMEZA Complete Matrix).

SARASOTA, Fla., Aug. 31, 2026 /PRNewswire-PRWeb/ -- "Transforming Wound Care Through Marine Science"

• Omeza® Holdings, Inc. is a U.S.-based ocean biotechnology company developing and commercializing marine-derived peptides and lipid products, with an FDA-cleared product, OCM™, already on the market and ongoing clinical programs to expand reimbursement and indications. Omeza products are formulated and manufactured in Sarasota, Florida. (USA)

Media Contact

Bernadette Cupit, OMEZA LLC, 1 9083344554, bcupit@omeza.com, https://omeza.com/

View original content to download multimedia:https://www.prweb.com/releases/omezas-ocm-will-be-featured-in-an-approved-abstract-treating-a-complex-chronic-burn-patient-at-fall-sawc-oct15-18-in-las-vegas-302862585.html

SOURCE OMEZA LLC